Evidence map›Paper›PMID 38751033›Full record

ReviewCancer control : journal of the Moffitt Cancer Center

BRAF-Mutated Melanoma Journey in Latin America: Expert Recommendations From Diagnosis to Treatment.

María A Bravo-Garzón, Leticia Bornstein-Quevedo, Veridiana Pires de Camargo, Gayatri Sanku, Angela Marie Jansen, Mariana Petaccia de Macedo, Mariana Rico-Restrepo, Matías Chacón

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

María A Bravo-GarzónLuis Carlos Sarmiento Angulo Cancer Treatment and Research Center - CTIC, Bogotá D.C., Colombia.
Leticia Bornstein-QuevedoInmunoQ, Mexico City, Mexico.
Veridiana Pires de CamargoBeneficienia Portuguesa de São Paulo, São Paulo, Brazil.
Gayatri SankuAmericas Health Foundation, Washington, DC, USA.
Angela Marie JansenAmericas Health Foundation, Washington, DC, USA.ORCID 0000-0003-2980-2421
Mariana Petaccia de MacedoRede D'Or, São Paulo, Brazil.
Mariana Rico-RestrepoAmericas Health Foundation, Bogota, Colombia.
Matías ChacónAlexander Fleming Institute, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectives• Gather a panel of Latin American experts in testing and treating

introductionMelanoma prevalence in Latin America is lower than in high- and middle-income countries. However, recent data indicate that the region's incidence and mortality are rising, with more stage IV patients being diagnosed. According to international clinical practice guidelines, conducting

methodsAmericas Health Foundation convened a meeting of Latin American experts on RESULTS AND

conclusionsSome recommendations for improving diagnostics through improving access and reducing the cost

Indexed as

MelanomaMutationProto-Oncogene Proteins B-rafHumansLatin AmericaPractice Guidelines as TopicSkin NeoplasmsProto-Oncogene Proteins B-rafBRAF-mutated melanomadigital pathologyguidelinesmelanoma in Latin Americaprecision medicine

Identifiers

PMID38751033
PMCPMC11100406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.